Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
2 Amyloid PET Imaging Agents Expand Labels as Lecanemab Approval Nears
Japan approved two amyloid PET imaging agents for their new indications on August 31 as the market awaits the official greenlight of Eisai’s lecanemab as the country’s first Alzheimer’s disease (AD)-modifying therapy. PDRadiopharma’s Amyvid Injection (florbetapir (18F)) and Nihon Medi-Physics’…
To read the full story
Related Article
- PDRadiopharma’s PET Imaging Agent Amyvid Widens Label Too
September 4, 2024
- PET Agent Vizamyl Approved for Use in Patients on Anti-Aβ Therapy
September 3, 2024
- As Leqembi Listing Approaches, Chuikyo OKs Coverage for PET Device and Diagnostics
November 27, 2023
BUSINESS
- Ferring, Nippon Kayaku to Co-Promote Bladder Cancer Gene Therapy
March 31, 2026
- Mochida to Acquire Urece from Fuji Yakuhin for 13.5 Billion Yen
March 31, 2026
- Sumitomo Files Latuda for Pediatric Schizophrenia in Japan
March 31, 2026
- Servier’s Glioma Drug Voranigo Now Available in Japan
March 31, 2026
- Otsuka to Acquire Transcend for US$700 Million, Snags PTSD Candidate
March 30, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…